Commonwealth Equity Services
SNDX icon

Commonwealth Equity Services’s Syndax Pharmaceuticals SNDX Stock Holding History

Commonwealth Equity Services’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-9,775
Closed -$228K – 4555
2026
Q1 		$228K Buy
+9,775
New +$212K ﹤0.01% 3873
2025
Q4 		– Sell
-10,906
Closed -$168K – 4434
2025
Q3 		$168K Buy
+10,906
New +$143K ﹤0.01% 3996
2023
Q4 		– Sell
-11,695
Closed -$170K – 4009
2023
Q3 		$170K Buy
11,695
+200
+2% +$3.78K ﹤0.01% 3444
2023
Q2 		$241K Buy
11,495
+605
+6% +$12.6K ﹤0.01% 3230
2023
Q1 		$230K Buy
+10,890
New +$271K ﹤0.01% 3193

Other funds holding SNDX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $13.8B AUM 163.97% 1-Year Est. Return

Commonwealth Equity Services's SNDX Position: Q2 2026 in Review

Commonwealth Equity Services sold out of Syndax Pharmaceuticals (SNDX) in Q2 2026, closing a stake of 9,775 shares — an estimated $228K sold.

Commonwealth Equity Services first reported a position in SNDX in Q1 2023 and held it in 5 quarters. The position peaked at $241K in Q2 2023. 242 funds tracked by Wall St. Rank hold SNDX as of Q2 2026.

  • Commonwealth Equity Services reported no remaining Syndax Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Commonwealth Equity Services sold 9,775 Syndax Pharmaceuticals shares in Q2 2026, an estimated $228K.
  • Commonwealth Equity Services first reported a position in Syndax Pharmaceuticals in Q1 2023 and held it in 5 quarters.
  • Commonwealth Equity Services's Syndax Pharmaceuticals position peaked at $241K in Q2 2023.
  • 242 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q2 2026.

Based on Commonwealth Equity Services's 13F filing for Q2 2026, filed 29 Jul 2026.